H3 Dynamics and Hylium Industries Join Forces to Progress Liquid Hydrogen-Electric Flight Capabilities
H3 Dynamics and Hylium Industries have joined forces to boost the performance of zero emission hydrogen-electric flight, by combining the strengths of Hylium’s liquid hydrogen storage and liquification solutions, and H3 Dynamics’ distributed hydrogen-electric propulsion nacelles, ultra-light fuel cells, and new hydrogen drone refueling stations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005162/en/
Joint development for transatlantic crossing with ISAE-SUPAERO Toulouse, H3 Dynamics - using HYLIUM Liquid hydrogen storage (Photo: Business Wire)
Moving to liquid hydrogen represents a significant capability leap for small electric-powered unmanned systems. Cryogenic (liquid) hydrogen stores 3 times more energy as compressed gas in the same given volume. This means delivery drones will be able to fly further, mapping and ISR missions could be done on a much bigger scale.
To illustrate the jump in performance, the same 25kg hydrogen-electric propulsion UAV demonstrated by H3 Dynamics last July in France, will be able to fly over 900km with a single fill. With pressurized hydrogen, that range reduces to 400km, which is still 3 times more than a battery-powered equivalent.
“When combined, our global best-in-class solutions achieve the global performance limit for low-altitude electric powered flight” says Taras Wankewycz, CEO H3 Dynamics. “We are proud to be working with Hylium to move hydrogen-electric flight propulsion to the next level”
Now all the various forms of hydogen drones and UAVs powered by H3 Dynamics including hydrogen airships, multi-rotors, vertical take-off and landing (VTOL), have a way to further boost flight durations by another factor of 3 over pressurized hydrogen systems, or a factor of 10 compared to batteries.
H3 Dynamics also recently announced a first hydrogen production, and automated hydrogen refueling mobile station for hydrogen UAV operations. Named H2FIELD the mobile station produces hydrogen from water and delivers compressed hydrogen gas tanks to the operator with little human intervention and no required hydrogen expertise. H3 Dynamics and Hylium’s partnership will upgrade the station so that it can fill liquid hydrogen tanks.
Developed in South Korea, Hylium’s breakthrough technology provides one of the most advanced solutions and has already been proven in a number of applications. South Korea is also leading the development for LH2 standardisation. One local proposal was accepted as a draft standard by a global ISO committee.
Hylium and H3 Dynamics technologies are currently being integrated to attempt a 3,300km crossing of the South Atlantic, in a program led by ISAE SUPAERO Toulouse, one of the world’s leading aerospace engineering schools. H3 Dynamics’ team developed a special fuselage design that can store a small LH2 tank and manage the thermal behavior of all the propulsion sub-systems.
LH2 technology will also be a next step in H3 Dynamics’ hydrogen-electric propulsor nacelles roadmap. A first twin engine cargo drone powered by these self-contained nacelles took off in the sky of Paris during the summer 2022, using 2 compressed hydrogen tanks – one in each nacelle. The goal now will be to switch them out for liquid hydrogen tanks with a lighter construction and a higher fuel capacity.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as hydrogen refueling and airport power solutions. The company has created a unique pathway to de-risk long term hydrogen aviation developments by starting commercially now with small, scalable solutions. H3 Dynamics employs 93 team members from its 3 regional headquarters in Toulouse, Austin and Singapore. It is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
About Hylium Industries: http://hylium-industries.com/
HYLIUM INDUSTRIES, INC. was established in 2014 as a Korea Institute of Science and Technology (KIST) venture company. Since then Hylium have been developing the Korea’s first cryogenic liquid hydrogen manufacturing and storage technologies with R&D support from the Korean Government.
Hylium has developed various technologies related to the hydrogen liquefaction system and owns over 20 patents and intellectual property rights, with more patents pending. In 2015 Hylium Industries’ technologies were acknowledged by the Cryogenic Engineering Conference with a Russel B. Scott Memorial Award for the Best Application in Small-Capacity Hydrogen Liquefaction Technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005162/en/
Contact information
Taras Wankewycz
CEO, H3 Dynamics
taras@h3dynamics.com
www.h3dynamics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom